Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12444889 | 0.79 | MAPT (0.39) | LMNASMN1; SMN2POLBHTT | |
| SCHEMBL2227349 | 0.79 | MAPT (0.39) | LMNASMN1; SMN2POLBHTT | |
| SCHEMBL2545031 | 0.78 | POLB (0.36) | LMNASMN1; SMN2POLBHTT | |
| SCHEMBL4095742 | 0.72 | BRD4 (0.40) | LMNASMN1; SMN2PARP1BRD4POLB | |
| SCHEMBL2227996 | 0.72 | NFATC1 (0.56) | NTRK1LMNAHTT | |
| SCHEMBL2227346 | 0.71 | MAP3K7 (0.34) | NTRK1LMNA | |
| SCHEMBL15724407 | 0.71 | KAT2B (0.41) | LMNASMN1; SMN2PARP1BRD4POLB | |
| SCHEMBL2227399 | 0.70 | NTRK1 (0.36) | NTRK1 | |
| SCHEMBL12444946 | 0.67 | KAT2B (0.56) | LMNASMN1; SMN2BRD4POLBHTT | |
| SCHEMBL28579341 | 0.67 | HTR3A (0.44) | BRD4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| WO-2010042337-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | BRIX1, REL, CNKSR1 | NTRK1 1360/4885LMNA 4525/4885SMN1; SMN2 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.